ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1342

Identification of Heterogenous Treatment Response Trajectories to anti-IL6 Receptor Treatment in Rheumatoid Arthritis

Joseph Patrick Michele Blair1, Cecilie Bager 2, Man Hung Eric Tang 2, Morten Karsdal 3, Anne Bay-Jensen 4 and Søren Brunak 5, 1Univeristy of Copenahgen, Copenhagen, Denmark, 2Nordic Bioscience ProScion, Copenhagen, Denmark, 3Nordic Bioscience, Copenhagen, Denmark, 4Nordic Bioscience, Herlev, Denmark, 5Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, Copenhagen, Hovedstaden, Denmark

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Personalized Medicine, Rheumatoid arthritis (RA), tocilizumab and bioinformatics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is a complex autoimmune disease with a fluctuating course of disease activity and progression. Although treatments have improved substantially in recent years thanks to the development of novel drugs, response is not guaranteed. Also, response is often monitored in a binary, and not a dynamic way, resulting in loss of information about the level of response. The aim of this study was to identify heterogeneity in Disease Activity Score 28 (DAS28) in response to tocilizumab in RA patients and investigate molecular and clinical factors which may cause this.

Methods: Longitudinal clinical and biochemical data, as well as baseline demographics for 485 RA patients receiving 4 or 8 mg/kg tocilizumab in combination with MTX, were extracted from the LITHE phase III clinical study (NCT00106535), and post-hoc and exploratory analysis was conducted. Latent class mixed models were used in order to identify distinct trajectories of patients’ disease activity using DAS28 after the initiation of treatment. The optimal number of classes was selected using Bayesian Information Criteria (BIC) and Akaike Information Criteria (AIC). Longitudinal and cross-sectional measurements were then analysed using linear mixed effects models in order to characterise patients by serological biomarker levels, and other clinical factors, and identify correlations between drug response and patient characteristics.

Results: Trajectory analysis identified three distinct response subgroups of patients: class 1 (n = 85, 25.9%), class 2 (n=338, 63.9%) and class 3 (n=62, 10.4%). All groups started with a high DAS28 on average (DAS28 > 5.1). Class 1 showed the least reduction in DAS28, with a significantly higher proportion of patients seeking escape therapy (p < 0.001). Class 3 showed significantly higher rates of improvement in DAS28 achieving remission status, as well as having the highest rates of patients achieving ACR response levels (p < 0.001). Biomarkers associated with inflammation, MMP-3, CRP, C1M, and C3M, were markedly decreased from baseline levels in class 3 in response to treatment compared to the other classes.

Conclusion: Identification of more distinct patient populations of drug response may allow for more targeted therapeutic treatment regimens. Treatment strategies should consider the initial state of disease severity as well as clinical and biochemical disease parameters to achieve optimal response rates.

All patient trajectories of DAS28 in response to Tocilizumab anti-IL6 treatment, with three identified latent trajectories of DAS28 in response to Tocilizumab over a 52-week clinical trial

Estimated marginal means for absolute change in the level of bone and inflammatory biomarkers after initiation of tocilizumab for each latent class


Disclosure: J. Blair, None; C. Bager, Nordic Biosceince Proscion, 3; M. Tang, Nordic Biosceince Proscion, 3; M. Karsdal, Nordic Biosceince, 1, 3, Nordic Bioscience, 1, 2, 3, 4, 5; A. Bay-Jensen, Nordic Bioscience, 1, 2, 3; S. Brunak, Nordic Biosceince Proscion, 6, Intomics, 6.

To cite this abstract in AMA style:

Blair J, Bager C, Tang M, Karsdal M, Bay-Jensen A, Brunak S. Identification of Heterogenous Treatment Response Trajectories to anti-IL6 Receptor Treatment in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/identification-of-heterogenous-treatment-response-trajectories-to-anti-il6-receptor-treatment-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-heterogenous-treatment-response-trajectories-to-anti-il6-receptor-treatment-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology